- Creative Medical Technology Holdings Inc (NASDAQ:CELZ) announced positive topline pilot study results for the StemSpine procedure using AlloStem to treat chronic lower back pain.
- The data demonstrated significant efficacy and no serious adverse events using the StemSpine ultrasound-guided non-surgical procedure for treating chronic lower back pain.
- The StemSpine procedure using AlloStem resulted in a greater than 90% reduction in narcotic usage, greater than 80% reduction in pain score, and greater than 50% reduction in the Oswestry Score in the treated patients.
- No patients required re-dosage or surgical intervention at the primary endpoint of six months, and there were no safety-related concerns.
- StemSpine using AlloStem is a patented procedure that utilizes an “off-the-shelf, ready-to-use” universal and proprietary allogenic (donor) cell.
- The patent issued to StemSpine includes using autologous (from the patient) and allogenic (universal donor) cells.
- In February 2023, Creative Medical announced three-year follow-up data for the company’s StemSpine pilot study.
- The three-year data demonstrated the continued efficacy of the StemSpine procedure for treating chronic lower back pain without any serious adverse effects reported.
- Price Action: CELZ shares are down 8.05% at $0.61 on the last check Thursday.
Why Nvidia Stock Is Surging Premarket Today
Nvidia Corp. (NASDAQ:NVDA) shares rose solidly in premarket trading, outperforming the Invesco QQQ Trust (NASDAQ:QQQ), an exchange-traded fund…
